This company has been marked as potentially delisted and may not be actively trading. Tocagen (TOCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TOCA vs. KALV, XNCR, CYCC, COGT, SION, BCYC, KROS, TYRA, MRVI, and GHRSShould you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include KalVista Pharmaceuticals (KALV), Xencor (XNCR), Cyclacel Pharmaceuticals (CYCC), Cogent Biosciences (COGT), Sionna Therapeutics (SION), Bicycle Therapeutics (BCYC), Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Maravai LifeSciences (MRVI), and GH Research (GHRS). These companies are all part of the "medical" sector. Tocagen vs. KalVista Pharmaceuticals Xencor Cyclacel Pharmaceuticals Cogent Biosciences Sionna Therapeutics Bicycle Therapeutics Keros Therapeutics Tyra Biosciences Maravai LifeSciences GH Research KalVista Pharmaceuticals (NASDAQ:KALV) and Tocagen (NASDAQ:TOCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk. Does the MarketBeat Community prefer KALV or TOCA? KalVista Pharmaceuticals received 106 more outperform votes than Tocagen when rated by MarketBeat users. Likewise, 75.05% of users gave KalVista Pharmaceuticals an outperform vote while only 66.03% of users gave Tocagen an outperform vote. CompanyUnderperformOutperformKalVista PharmaceuticalsOutperform Votes34975.05% Underperform Votes11624.95% TocagenOutperform Votes24366.03% Underperform Votes12533.97% Do insiders & institutionals believe in KALV or TOCA? 21.4% of Tocagen shares are held by institutional investors. 10.5% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 10.9% of Tocagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is KALV or TOCA more profitable? KalVista Pharmaceuticals has a net margin of 0.00% compared to Tocagen's net margin of -176,433.34%. KalVista Pharmaceuticals' return on equity of -103.92% beat Tocagen's return on equity.Company Net Margins Return on Equity Return on Assets KalVista PharmaceuticalsN/A -103.92% -88.06% Tocagen -176,433.34%-327.74%-111.87% Which has higher valuation & earnings, KALV or TOCA? Tocagen has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalVista PharmaceuticalsN/AN/A-$126.64M-$3.72-3.19Tocagen$40K4,550.59-$63.52M-$2.69-2.83 Does the media favor KALV or TOCA? In the previous week, KalVista Pharmaceuticals had 8 more articles in the media than Tocagen. MarketBeat recorded 8 mentions for KalVista Pharmaceuticals and 0 mentions for Tocagen. KalVista Pharmaceuticals' average media sentiment score of 1.12 beat Tocagen's score of 0.00 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment KalVista Pharmaceuticals Positive Tocagen Neutral Which has more risk and volatility, KALV or TOCA? KalVista Pharmaceuticals has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500. Comparatively, Tocagen has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Do analysts rate KALV or TOCA? KalVista Pharmaceuticals presently has a consensus price target of $24.83, suggesting a potential upside of 109.21%. Given KalVista Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe KalVista Pharmaceuticals is more favorable than Tocagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Tocagen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryKalVista Pharmaceuticals beats Tocagen on 12 of the 18 factors compared between the two stocks. Get Tocagen News Delivered to You Automatically Sign up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TOCA vs. The Competition Export to ExcelMetricTocagenPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$182.02M$6.52B$5.37B$8.38BDividend YieldN/A2.65%5.22%4.11%P/E Ratio-3.218.9226.8419.71Price / Sales4,550.59253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book16.916.466.794.50Net Income-$63.52M$143.98M$3.23B$248.18M Tocagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TOCATocagenN/A$7.61+1.5%N/A+1,135.4%$182.02M$40,000.00-3.2177Gap UpKALVKalVista Pharmaceuticals4.3055 of 5 stars$11.64-4.4%$24.83+113.3%+3.0%$578.69MN/A-3.20100News CoveragePositive NewsXNCRXencor3.7047 of 5 stars$8.11-7.5%$29.50+263.7%-65.7%$577.04M$127.23M-2.53280CYCCCyclacel Pharmaceuticals0.4929 of 5 stars$2.75-23.4%N/A-95.0%$570.17M$43,000.00-0.2914Analyst ForecastGap DownHigh Trading VolumeCOGTCogent Biosciences2.3651 of 5 stars$4.99-2.7%$14.29+186.3%-32.3%$568.14MN/A-2.0180News CoveragePositive NewsAnalyst ForecastGap DownSIONSionna TherapeuticsN/A$12.82-0.6%$38.50+200.3%N/A$565.67MN/A0.0035BCYCBicycle Therapeutics3.7903 of 5 stars$8.11-5.7%$25.00+208.3%-60.8%$561.65M$25.72M-2.47240KROSKeros Therapeutics3.2291 of 5 stars$13.47-2.0%$37.00+174.7%-73.0%$547.08M$214.71M-2.59100Positive NewsTYRATyra Biosciences1.678 of 5 stars$9.98-2.7%$30.83+209.0%-46.7%$529.84MN/A-6.2020News CoveragePositive NewsAnalyst ForecastAnalyst RevisionMRVIMaravai LifeSciences4.0768 of 5 stars$2.06-2.8%$6.64+222.3%-78.8%$523.93M$259.19M-1.26610GHRSGH Research2.5594 of 5 stars$10.06-1.0%$30.43+202.5%-6.3%$523.40MN/A-12.7310 Related Companies and Tools Related Companies KalVista Pharmaceuticals Alternatives Xencor Alternatives Cyclacel Pharmaceuticals Alternatives Cogent Biosciences Alternatives Sionna Therapeutics Alternatives Bicycle Therapeutics Alternatives Keros Therapeutics Alternatives Tyra Biosciences Alternatives Maravai LifeSciences Alternatives GH Research Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TOCA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tocagen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tocagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TOCA Stock Free TOCA Stock Alerts